BP-Cx-1

BP-Cx-1 A globular polydentant ligand, is a refined polymer of the benzo-poly-carbonic family.  BP-Cx-1 has a number of favorable biochemical and therapeutic properties.   BP-Cx-1 is capable …

Read more

BP-C1

BP-C1 Is based on a combination of BP-Cx-1 and platinum.  It contains approximately 100 times less platinum than ordinary doses of Cisplatin used in chemotherapeutical …

Read more

BP-C2

BP-C2 The company’s second product is BP-C2, which is based on BP-Cx-1 combined with molybdenum salts.  BP-C2 is in preclinical development as an oral agent …

Read more

BP-Cx-1

BP-Cx-1 A globular polydentant ligand, is a refin...

BP-C1

BP-C1 Is based on a combination of BP-Cx-1 and pl...

BP-C2

BP-C2 The company’s second product is BP-C2, wh...

About us

The Company.

 

Meabco is a Biotech Company primarily focused on oncology and radiation protection.

 

The company was established in 2000, and its head office is located in Copenhagen, Denmark

Products

 

BP-Cx-1 - Meabco’s product portfolio is based on the combination of BP-Cx-1 and metal ions of known therapeutic potential.  BP-Cx-1, a globular polydentant ligand, is a refined natural substance, based on acid polymers of the benzo-poly-carbonic family.  BP-Cx-1 is capable of chelating/encapsulating the metal ions, and facilitates their uptake into cells.

 

BP-C1 - BP-C1 is based on a combination of BP-Cx-1 and platinum.  It contains approximately 100 times less platinum than ordinary doses of Cisplatin used in chemotherapeutical drugs, resulting in a much enhanced safety profile.  At the same time, clinical efficacy is maintained or improved due to the carrier effect of the polymer.

 

BP-C2 - The company’s second product is BP-C2, which is based on BP-Cx-1 combined with molybdenum salts.  BP-C2 is in preclinical development for prevention of side effects arising from cancer radiotherapy, nuclear radiation and irradiation at large.